Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
ETAMSILATE
OM PHARMA SA
250/2
Solution for Injection
1998-04-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dicynene 250mg/2 ml Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient is etamsylate 125mg/ml of injection solution. (250mg per 2 ml ampoule). Excipients: Each 2ml ampoule also contains 0.8mg of sodium metabisulphite (E223) For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solution for injection (injection). A clear, colourless, aqueous solution for injection (pH 6.2 to 6.8). 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS DICYNENE is used clinically for the prophylaxis and treatment of periventricular hemorrhage in low birth weight infants. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Neonates only: The normal dosage is 12.5mg/kg given by intravenous or intramuscular route within an hour of birth and every six hours for the first 4 days of life. 4.3 CONTRAINDICATIONS Use in patients with a known hypersensitivity to etamsylate or to any of the excipients. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE The product contains sulfites which may cause an anaphylactic reaction (see 4.8 Undesirable Effects). If the infant develops a fever then treatment should be discontinued. DICYNENE injection is intended for neonatal use only. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION DICYNENE injection is incompatible with solutions of sodium bicarbonate and compound sodium lactate. When DICYNENE injection is mixed with saline it should be used immediately. 4.6 FERTILITY, PREGNANCY AND LACTATION Clinical use is not relevant for this indication. 4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 31/03/2011_ _CRN 2056958_ Les hele dokumentet